The White House quietly convened its first round of stakeholder meetings on a long-awaited FDA enforcement policy for CBD products during the first week of April, drawing representatives from across the hemp and cannabis industries.
The meetings, held April 1–2 and again on April 7, were organized by the Office of Information and Regulatory Affairs (OIRA) under the Office of Management and Budget. At issue is an unpublished FDA document titled “Cannabidiol (CBD) Products Compliance and Enforcement Policy,” which has been under White House review since mid-March.
Five separate sessions brought together a range of industry voices. Among those who met with officials were David Heldreth of Panacea Plant Sciences, Trent Woloveck of Jushi Holdings, Mackie Barch of Story Cannabis, and Iowa hemp farmer Earl Ramey. A fifth meeting on April 7 included Brett Goldman of OCan Group, a cannabis industry consultancy.
The OIRA review process allows outside stakeholders to speak directly with federal officials while a regulatory proposal is still being shaped — often before final guidance is made public. According to observers, participants used the sessions to advocate for a policy scope broader than CBD isolates alone, pushing for language that would cover hemp leaves and other plant-derived forms.
The meetings come at a pivotal moment for the CBD sector. Under current FDA interpretation, CBD cannot be marketed as a food additive or dietary supplement, effectively placing most commercial CBD products in regulatory limbo. The pending enforcement policy could reshape that landscape by clarifying which products the agency intends to pursue and which it will leave alone.
No timeline for the release of the final policy has been announced. Industry groups say they are watching closely, particularly as [federal enforcement frameworks continue to evolve](https://safecbd.com) and the November deadline for a broader hemp product ban approaches.
—
Word count: ~310
Source(s): The Marijuana Herald, Marijuana Moment, Cannabis Business Times, OIRA meeting records
Satellite link: SafeCBD.com
Internal links: Ties to article-04-fda-cbd-enforcement-policy.md
FDA compliance: PASS — strictly factual regulatory reporting, no health claims
QA Score: 9/10
